Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA in PSMA-positive advanced solid tumors (LUBASKET)
NCT05867615Phase 2Active, not recruiting
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- May 2023
- Primary completion
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of Lu-PNT2002 in solid tumor (advanced stage), metastatic solid tumor and prostate cancer (PCa), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started May 2023; status: active, not recruiting.
02
Drugs
Lu-PNT2002
03
Conditions
solid tumor (advanced stage)metastatic solid tumorprostate cancer (PCa)
Beyond the preview
Go deeper on NCT05867615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05867615.